The TFPI 536C →T Mutation Is not Associated with Increased Risk for Venous or Arterial Thrombosis

• References

• 1 Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 453-6.
• 2 Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-7.
• 3 Kleesiek K, Schmidt M, Götting C, Schwenz B, Lange S, Müller-Berghaus G, Brinkmann T, Prohaska W. The 536C→T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999; 82: 1-5.
• 4 Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V. Polymorphisms of platelet membrane glycoprotein Ibα associated with arterial thrombotic disease. Blood 1998; 92: 2771-6.
• 5 Corral J, Iniesta JA, González-Conejero R, Vicente V. Detection of Factor V Leiden form a drop of blood by PCR-SSCP. Thromb Haemost 1996; 76: 735-7.
• 6 Corral J, González-Conejero R, Lozano ML, Rivera J, Heras I, Vicente V. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not associated with arterial disease. Br J Haematol 1997; 99: 304-7.
• 7 Ridker PM, Hennekens CH, Lindpaintner K, Stampfler MJ, Eisenberg PR, Miletich JP. Mutation in the gene for coagulation factor V and the risk for myocardial infarction, stroke and venous thrombosis in apparently healthy men. Lancet 1998; 351: 88-92.